.
MergerLinks Header Logo

Announced

Completed

ARCH Venture Partners and Monograph Capital led a $120m funding round in Human Immunology Biosciences.

Financials

Edit Data
Transaction Value£104m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Sources

Edit

Tags

Edit

Minority

clinical-stage biotechnology

Biotechnology

Venture Capital

Private

Private Equity

Domestic

Single Bidder

Acquisition

Friendly

biotechnology company

Completed

United States

Synopsis

Edit

Investment firms ARCH Venture Partners and Monograph Capital led a $120m funding round in Human Immunology Biosciences, a clinical-stage biotechnology company, with participation from Jeito Capital. "We know the power of precision medicine to achieve better results for patients, and HI-Bio is the first company to combine that approach with a focus on the latest in genetics and immunology for immune-mediated diseases," Paul Berns, ARCH Ventures Managing Director.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US